THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [6.7]-C35 ID: TIP-MED-000305

Dexamethasone

Active Ingredient / Scientific Identity: Dexamethasone • Class: Intermediate-Acting & Long-Acting Systemic Glucocorticoids (Schedule H | NLEM 2022)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Dexamethasone ([6.7]-C35 | ID: TIP-MED-000305) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/6-7-c35-dexamethasone/
Generic / Entity NameDexamethasone ([6.7]-C35)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassIntermediate-Acting & Long-Acting Systemic Glucocorticoids (Schedule H | NLEM 2022)
Available Dosage FormsMethylprednisolone Tablets: 4 mg, 8 mg, 16 mg; IV Succinate: 40 mg, 125 mg, 500 mg, 1000 mg. Dexamethasone Tab
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal & Hepatic: No dose reduction needed, but monitor fluid/electrolytes in CKD and cirrhosis
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Dexamethasone (TIP-MED-000305, Reference Code [6.7]-C35) is classified under Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06) as a Intermediate-Acting & Long-Acting Systemic Glucocorticoids (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [6.7] (Methylprednisolone & Dexamethasone). Representative Indian Market Examples (Edition 2.7 Ch 06 [6.7], p. 75): Methylprednisolone: Medrol (Pfizer), Ivepred / Zempred (Sun), Solu-Medrol (IV). Dexamethasone: Dexona (Zydus), Decdan (Wockhardt) — Strengths & Dosage Forms: Methylprednisolone Tablets: 4 mg, 8 mg, 16 mg; IV Succinate: 40 mg, 125 mg, 500 mg, 1000 mg. Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg; Injection: 4 mg/mL (Prednisolone 5 mg = Methylprednisolone 4 mg = Dexamethasone 0.75 mg)
Co-indexed constituent under primary monograph [6.7] (Methylprednisolone & Dexamethasone). Representative Indian Market Examples (Edition 2.7 Ch 06 [6.7], p. 75): Methylprednisolone: Medrol (Pfizer), Ivepred / Zempred (Sun), Solu-Medrol (IV). Dexamethasone: Dexona (Zydus), Decdan (Wockhardt) — Strengths & Dosage Forms: Methylprednisolone Tablets: 4 mg, 8 mg, 16 mg; IV Succinate: 40 mg, 125 mg, 500 mg, 1000 mg. Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg; Injection: 4 mg/mL (Prednisolone 5 mg = Methylprednisolone 4 mg = Dexamethasone 0.75 mg)
Dosage Forms & Available Strengths:
Methylprednisolone Tablets: 4 mg, 8 mg, 16 mg; IV Succinate: 40 mg, 125 mg, 500 mg, 1000 mg. Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg; Injection: 4 mg/mL (Prednisolone 5 mg = Methylprednisolone 4 mg = Dexamethasone 0.75 mg)
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Intermediate-Acting & Long-Acting Systemic Glucocorticoids (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Thyroid, Pituitary, Adrenal & Hormonal Medicines (Ch 06): clinical efficacy is mediated via Intermediate-Acting & Long-Acting Systemic Glucocorticoids (Schedule H | NLEM 2022) for Methylprednisolone: Acute asthma/COPD exacerbations, rheumatoid/lupus flares, severe allergic reactions, MS/lupus nephritis IV pulse. Dexamethasone: Cerebral oedema, bacterial meningitis adjunct, severe croup, CINV, hypoxic COVID/ARDS, foetal lung maturation (6 mg IM q12h x 4 doses).

4. Therapeutic Indications & Evidence-Supported Uses

  • Methylprednisolone: Acute asthma/COPD exacerbations, rheumatoid/lupus flares, severe allergic reactions, MS/lupus nephritis IV pulse
  • Dexamethasone: Cerebral oedema, bacterial meningitis adjunct, severe croup, CINV, hypoxic COVID/ARDS, foetal lung maturation (6 mg IM q12h x 4 doses)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Methylprednisolone Oral: 4–48 mg PO OD in the morning; IV Pulse: 500–1000 mg IV over 60 min x 3–5d. Dexamethasone: 0.5–8 mg/day PO/IV (Cerebral oedema: 4 mg q6h; Croup: 0.15–0.6 mg/kg single dose)

Administration & Meal Timing: Take oral doses WITH or immediately after breakfast (8:00 AM) to mimic physiological morning cortisol peak and protect gastric mucosa | Morning (8:00 AM with Breakfast) for anti-inflammatory regimens

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [6.7].
Metabolism & Biotransformation:
Renal & Hepatic: No dose reduction needed, but monitor fluid/electrolytes in CKD and cirrhosis
Elimination & Renal Adjustment:
Renal & Hepatic: No dose reduction needed, but monitor fluid/electrolytes in CKD and cirrhosis
Hepatic Impairment Considerations:
Renal & Hepatic: No dose reduction needed, but monitor fluid/electrolytes in CKD and cirrhosis

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in untreated systemic fungal infections and administration of live viral vaccines (at immunosuppressive doses for >=2 weeks). Dexamethasone has ZERO mineralocorticoid activity (preferred in cerebral oedema/HF)

Key Clinical Precautions: Renal & Hepatic: No dose reduction needed, but monitor fluid/electrolytes in CKD and cirrhosis

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hyperglycaemia (peaks in afternoon/evening!), insomnia, mood changes/euphoria, epigastric dyspepsia, fluid retention, increased appetite
  • Secondary adrenal insufficiency / Addisonian crisis on abrupt withdrawal, GI ulceration/bleeding (especially with NSAIDs!), avascular necrosis of femoral head, osteoporosis, opportunistic infections (TB reactivation, mucormycosis in uncontrolled diabetes!), steroid psychosis, cataracts
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • NSAIDs/Aspirin increase peptic ulcer/bleed risk 4-fold (co-prescribe a PPI!); CYP3A4 inducers (Rifampicin, Phenytoin, Carbamazepine) double Dexamethasone/Methylprednisolone clearance; CYP3A4 inhibitors (Clarithromycin, Itraconazole) cause iatrogenic Cushing's; antagonises antidiabetics & antihypertensives

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [6.7].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Take at 8:00 AM after breakfast to prevent sleeplessness and stomach upset; diabetic patients must check afternoon blood sugars closely; never stop long-term steroids without a doctor's tapering schedule
    • Meal & Clock Timing Instruction: Take oral doses WITH or immediately after breakfast (8:00 AM) to mimic physiological morning cortisol peak and protect gastric mucosa (Morning (8:00 AM with Breakfast) for anti-inflammatory regimens)
    • Missed Dose Protocol: Take as soon as remembered on the same day; never stop a >2-week course suddenly
    • Geriatric Dispensing Pearl: High risk of delirium, hyperglycaemia, proximal myopathy, and osteoporotic vertebral fractures in older adults

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Methylprednisolone Tablets: 4 mg, 8 mg, 16 mg; IV Succinate: 40 mg, 125 mg, 500 mg, 1000 mg. Dexamethasone Tablets: 0.5 mg, 4 mg, 8 mg; Injection: 4 mg/mL (Prednisolone 5 mg = Methylprednisolone 4 mg = Dexamethasone 0.75 mg)

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    ← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
    Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/6-7-c35-dexamethasone/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.